Displaying 1 - 10 of 10

Display:

12 24 48

Immune-Mediated and Cholestatic Diseases

3

CymaBay Therapeutics: “Targeting New Approaches in PBC” - EASL Congress 2024

View

Immune-Mediated and Cholestatic Diseases

3

CymaBay Therapeutics: “Targeting New Approaches in PBC” - EASL Congress 2024

View

Immune-Mediated and Cholestatic Diseases

3

CymaBay Therapeutics: “Targeting New Approaches in PBC” - EASL Congress 2024

View

Immune-Mediated and Cholestatic Diseases

7

CymaBay Therapeutics: Taking Aim at Primary Biliary Cholangitis - EASL Congress 2024

View

Immune-Mediated and Cholestatic Diseases

7

CymaBay Therapeutics: Taking Aim at Primary Biliary Cholangitis - EASL Congress 2024

View

Immune-Mediated and Cholestatic Diseases

7

CymaBay Therapeutics: Taking Aim at Primary Biliary Cholangitis - EASL Congress 2024

View

Immune-Mediated and Cholestatic Diseases

7

CymaBay Therapeutics: Taking Aim at Primary Biliary Cholangitis - EASL Congress 2024

View

Immune-Mediated and Cholestatic Diseases

7

CymaBay Therapeutics: Taking Aim at Primary Biliary Cholangitis - EASL Congress 2024

View

Immune-Mediated and Cholestatic Diseases

7

CymaBay Therapeutics: Taking Aim at Primary Biliary Cholangitis - EASL Congress 2024

View

Immune-Mediated and Cholestatic Diseases

7

CymaBay Therapeutics: Taking Aim at Primary Biliary Cholangitis - EASL Congress 2024

View

Displaying 1 - 10 of 10

Display:

12 24 48